Table 1.

Patient, tumor, and treatment characteristics

CharacteristicsValues
Total no. of patients89
Age (y), median (range)  51 (31–77)
Stage at diagnosis—no. (%)
 15 (6)
 27 (8)
 363 (71)
 48 (9)
 Not known6 (7)
Histology grade—no. (%)
 213 (15)
 366 (74)
 Not known10 (11)
Histology—no. (%)
 Serous papillary67 (75)
 Endometrioid7 (8)
 Adenocarcinoma not otherwise specified15 (17)
Prior no. of lines of systemic chemotherapy (excluding olaparib)—no. (%)
 113 (15)
 230 (34)
 323 (26)
 ≥421 (24)
 Not known2 (2)
BRCA mutation status—no. (%)
BRCA166 (74)
BRCA223 (26)
Optimally debulked—no. (%)
 Yes48 (54)
 No23 (26)
 Not known18 (20)
Previous breast cancer—no. (%)
 Yes29 (33)
 Chemotherapy for breast cancer11 (38)
 No60 (67)
Sensitivity to last pre-PARPi platinum chemotherapy—no. (%)
 Sensitive (TFI >12 m)15 (17)
 Partially sensitive (TFI >6 and ≤12 m)38 (43)
 Resistant (TFI <6 m)36 (40)
Overall response rate to olaparib—no. of responses/no. evaluable (%)
 RECIST34/86 (40)
 RECIST and/or CA12541/87 (47)